Protagonist Therapeutics, Inc. (PTGX) Financial Statements
Protagonist Therapeutics, Inc. (PTGX) reported trailing twelve-month revenue of $282.0M (up 34.8% year on year) and net income of $82.9M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $130.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PTGXProtagonist Therapeutics, Inc.Follow PTGX — free
—
Price chart with a free account
- Market cap
- 9.0B
- P/E TTM
- 135.7
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 30.9 | 0.2 | 28.6 | 27.4 | 26.6 | 60.0 | 434.4 | 46.0 | 282.0 | |
| Research & development | 59.5 | 65.0 | 74.5 | 126.0 | 126.2 | 120.2 | 138.1 | 159.3 | 175.2 | |
| Operating income | -42.3 | -80.5 | -64.5 | -125.8 | -131.4 | -93.7 | 252.8 | -158.1 | 58.3 | |
| Pre-tax income | -39.7 | -77.9 | -64.8 | -125.6 | -127.4 | -79.0 | 279.4 | -129.3 | 84.3 | |
| Income tax | -0.8 | -0.7 | 1.3 | 0.0 | 0.0 | 0.0 | 4.2 | 0.8 | 1.4 | |
| Net income | -38.9 | -77.2 | -66.2 | -125.6 | -127.4 | -79.0 | 275.2 | -130.1 | 82.9 | |
| Diluted EPS ($) | -1.74 | -2.98 | -1.92 | -2.71 | -2.60 | -1.39 | 4.23 | -2.05 | 1.02 | |
| Diluted shares (mn) | — | — | — | — | 49.0 | 56.8 | 65.1 | 63.6 | — |
USD millions · SEC XBRL
Protagonist Therapeutics, Inc. — questions
- What is Protagonist Therapeutics, Inc.'s revenue?
- $282.0M over the twelve months to 2026-06-30, up 34.8% year on year, from its 10-Q and 10-K filings.
- What is Protagonist Therapeutics, Inc.'s net income?
- $82.9M over the twelve months to 2026-06-30.
- What is Protagonist Therapeutics, Inc.'s free cash flow?
- $130.6M over the twelve months to 2026-06-30.
- What are Protagonist Therapeutics, Inc.'s diluted earnings per share?
- $1.02 over the twelve months to 2026-06-30.
Every figure on this page comes from Protagonist Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.